Abstract:Objective: The aim of the current study was to investigate the effects of radioactive iodine-125 seed implantation on therapeutic efficacy, serum vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA) levels, and prognosis of patients with ocular malignant tumors. Methods: A total of 86 patients with ocular malignant tumors were randomly allocated into the adjuvant chemotherapy group or iodine-125 seed implantation group, based on a random number table, with 43 patients in each group. The chemotherapy group underwent ocular tumor resections and routine postoperative adjuvant chemotherapy, while the iodine-125 group was treated with tumor resections and intraoperative iodine-125 seed implantation. At 3 months after surgery, after the chemotherapy group had received 2 cycles of chemotherapy, total effective rates were accessed in both groups. Serum CEA levels, before and after treatment, were detected by automatic electrochemiluminescence. Serum VEGF levels were also measured, before and after treatment, in both groups via ELISA. Correlation levels between CEA and VEGF were analyzed. Incidence rates of side effects, during treatment, were recorded and compared between the two groups. One-year progression-free survival and 3-year survival rates of the two groups were compared via regular follow-ups. Results: The total effective rate of the iodine-125 group was higher than that of chemotherapy group (P<0.05). In addition, expression levels of serum CEA and VEFG in the two groups, after treatment, were lower than those before treatment (all P<0.05). Decreases in the iodine-125 group were more significant than those in the chemotherapy group (both P<0.05). Serum CEA levels and VEGF levels were positively correlated. Incidence of side effects in the iodine-125 group was significantly lower than that in the chemotherapy group (P<0.05). Furthermore, 1-year progression-free survival and 3-year survival rates in the iodine-125 group were higher than those in the chemotherapy group. Differences were statistically significant (both P<0.05). Conclusion: Radioactive iodine-125 seed implantation in patients with ocular malignant tumors can effectively improve therapeutic efficacy, reduce serum levels of tumor markers CEA and VEGF, and improve 1-year progression-free survival and 3-year survival rates. This method shows a high level of safety. Thus, it is highly recommended for clinical practice.

Effect of octreotide on cell proliferation in pancreatic adenocarcinoma

The effects of Octreotide on proliferation、apoptosis and VEGF expression in human pancreatic cancer cell line

The Effect of Octreotide on Growth Inhibition of Subcutaneous Implanted Tumor with Human Gallbladder Carcinoma in Nude Mice

Anti-tumor Activity of Emodin on Human Pancreatic Cancer Cell Line BXPC-3 in Vivo

Effect of K‐ras Antisense Oligodeoxynucleotides on Human Pancreatic Cancer Cell Line PaTu 8988S

Effect of Octreotide on Angiogenesis Induced by Hepatocellular Carcinoma in Vivo

Anti-carcinoma Effect of Targeted Radiotherapy Using 90Y-Dota-octreotide Mediated by Somatostatin Receptor

EFFECTS OF DIFFERENT CONCENTRATIONS OF ANTISENSE OLIGODEOXYNUCLEOTIDES(ASODN) ON HUMAN PANCREATIC CANCER CELL LINE PaTu8988s

Effects Of Radioactive Iodine-125 Seed Implantation On Therapeutic Efficacy, Serum Vegf, Cea Levels, And Prognosis Of Patients With Ocular Malignant Tumors

Octreotide Acts As an Antitumor Angiogenesis Compound and Suppresses Tumor Growth in Nude Mice Bearing Human Hepatocellular Carcinoma Xenografts.

The Effect of Octreotide on Proliferation and P-glycoprotein Expresslon of SGC-7901 Cell Line

Direct effects of octreotide on osteoblast cell proliferation and function

Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment

[Effect of Triptolide on Human Oral Cancer Cell Proliferation and PTEN Gene Mrna Expression in Oral Cancer].

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas

Effect of Parthenolide on Proliferation and Apoptosis of Human Pancreatic BxPC-3 Cells

Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

Octreotide Inhibit the Proliferation Induced by Autocrine Interleukin-6 in Cholangiocarcinoma Cell Lines

Parthenolide Induces Proliferation Inhibition and Apoptosis of Pancreatic Cancer Cells in Vitro

The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers